Evaluation of Reference variability [Design Issues]

posted by Nirali  – India, 2009-04-13 13:53 (5849 d 19:37 ago) – Posting: # 3515
Views: 4,690

Dear All,

We want to conduct BE replicate study to demonstrate that the within-subject variability for Cmax of the reference compound in the study is >30% for EU regulatory.

To check reference variablity which study design and model shall be used for statistical analysis?

Shall we use 2-period replicate design to assess the inter and intra-subject variability of reference drug, in which reference drug given in both the periods?

Thanks & Regards,
NIRALI

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,703 registered users;
22 visitors (0 registered, 22 guests [including 5 identified bots]).
Forum time: 09:31 CEST (Europe/Vienna)

Do not put your faith in what statistics say until you have carefully
considered what they do not say.    William W. Watt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5